Maryland Heights, MO, March 04, 2017 --(PR.com
)-- The global hospital acquired disease testing market was valued at USD 564 Million in 2015 and is estimated to reach USD 1.2 Billion by 2020, at a CAGR of 17.5% from 2016 to 2020, due to rising drug resistant pathogens worldwide.
Browse Hospital Acquired Disease Testing Market by Test Type (Blood Stream Associated Infection, MRSA Infection, Hospital-Acquired Pneumonia, Surgical Associated Infection, UTI, Gastroenteritis, Puerperal Fever) 2016-2020 at https://www.ihealthcareanalyst.com/report/hospital-acquired-disease-testing-market/.
Hospital-acquired infection (HAI) or nosocomial infection can be contracted from the environment or staff of a healthcare facility. It can be spread in the hospital environment, nursing home environment, rehabilitation facility, clinic, or other clinical settings. The recent global resurgence of HAIs including discovery of new pathogens, recurrence of old infections and rapid spread of antimicrobial resistant pathogens. Diagnosis of such diseases is essential for prompt and efficient treatment of patients thereby reducing the overall duration of hospital stay, cost of healthcare, patient morbidity and mortality rates. HAIs are considered as a significant cause of death and are acquired while receiving healthcare treatment. Rapid adoption of advanced molecular diagnostics methods, well defined regulatory framework and observation guidelines are the major factors driving the North America hospital acquired disease testing market.
The global hospital acquired disease testing market report estimates the market size (Revenue USD million - 2013 to 2020) for market segmentation based on disease test (blood stream associated infection, MRSA infection, Hospital-acquired pneumonia, surgical associated infection, UTI, Gastroenteritis, puerperal fever, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global hospital acquired disease testing market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
The global hospital acquired disease testing market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global hospital acquired disease testing market and included in this report are Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche, Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc. and others.
To request Table of Contents and Sample Pages of this report visit:
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043